‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
March 16, 2021
“[Chapter one] of the guidelines is devoted to blood pressure measurement ... if [targeting] 120 [mm Hg systolic], the emphasis is on 120 measured properly.”
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
April 21, 2020
Post hoc analyses of data from as many as 46,000 patients showed surprising links between PCSK9 inhibition and reduced rates of VTE and aortic stenosis.
Larger absolute rivaroxaban benefit in diabetes: COMPASS
March 29, 2020
The new vascular low dose of rivaroxaban has had a slow start, but these results may stimulate use in patients with diabetes and stable disease.
COPD linked to higher in-hospital death rates in patients with PAD
January 22, 2019
COPD was an independent predictor of in-hospital death and of pulmonary embolism in PAD patients.
VIDEO: Rivaroxaban plus aspirin cut cardiovascular events in stable patients
August 28, 2017
BARCELONA – The COMPASS trial produced “unambiguous results that should change guidelines and the management of stable coronary artery disease,” commented Eugene Braunwald, MD.
PVC phlebitis rates varied widely, depending on assessment tool
August 21, 2017
Rates also varied within individual instruments because they included several possible case definitions.
FDA approves betrixaban for VTE prophylaxis
June 23, 2017
An orally administered agent has been approved for VTE prophylaxis in at risk hospitalized patients.
Preoperative VTEs occurred in 10% of cancer patients
March 27, 2017
SEATTLE – Those with preoperative VTEs were significantly more likely to experience postoperative complications.